Tirzepatide
LY3298176
Tirzepatide is a synthetic peptide studied in in-vitro and preclinical research as a dual agonist of the GLP-1 and GIP receptors. Research reagent only — not for human consumption or medical use.
Key facts
- Class
- Dual incretin agonist
- Targets
- GLP-1 / GIP
- Form
- Lyophilised (powder)
- Status
- Research Use Only
Study library
All results on PubMedTirzepatide for Obesity Treatment and Diabetes Prevention.
Jastreboff AM, et al. · The New England journal of medicine · 2025
Effect of Subcutaneous Tirzepatide vs Placebo Added to Titrated Insulin Glargine on Glycemic Control in Patients With Type 2 Diabetes: The SURPASS-5 Randomized Clinical Trial.
Dahl D, et al. · JAMA · 2022
Tirzepatide is an imbalanced and biased dual GIP and GLP-1 receptor agonist.
Willard FS, et al. · JCI insight · 2020
Tirzepatide vs Insulin Lispro Added to Basal Insulin in Type 2 Diabetes: The SURPASS-6 Randomized Clinical Trial.
Rosenstock J, et al. · JAMA · 2023
Tirzepatide as a Potential Disease-Modifying Therapy in Lipedema: A Narrative Review on Bridging Metabolism, Inflammation, and Fibrosis.
Viana DPDC, et al. · International journal of molecular sciences · 2025
Effects of subcutaneous tirzepatide versus placebo or semaglutide on pancreatic islet function and insulin sensitivity in adults with type 2 diabetes: a multicentre, randomised, double-blind, parallel-arm, phase 1 clinical trial.
Heise T, et al. · The lancet. Diabetes & endocrinology · 2022
Efficacy and safety of tirzepatide for treatment of overweight or obesity. A systematic review and meta-analysis.
Tan B, et al. · International journal of obesity (2005) · 2023
Tirzepatide as Compared with Semaglutide for the Treatment of Obesity.
Aronne LJ, et al. · The New England journal of medicine · 2025
Efficacy and safety of tirzepatide in children and adolescents with type 2 diabetes (SURPASS-PEDS): a randomised, double-blind, placebo-controlled, phase 3 trial.
Hannon TS, et al. · Lancet (London, England) · 2025
Population pharmacokinetics of the GIP/GLP receptor agonist tirzepatide.
Schneck K, et al. · CPT: pharmacometrics & systems pharmacology · 2024
Body composition changes during weight reduction with tirzepatide in the SURMOUNT-1 study of adults with obesity or overweight.
Look M, et al. · Diabetes, obesity & metabolism · 2025
Tirzepatide for adults living with obesity.
Franco JV, et al. · The Cochrane database of systematic reviews · 2025
Results retrieved live from PubMed (NCBI). Research literature only — no medical advice.
Research peptides — Research Use Only
- Not for human consumption
- Not for the diagnosis, treatment or prevention of any disease